A Team of World-Class Science and Industry Leaders

Susan has extensive R&D and business leadership experience across the life sciences and technology industries. Adept at shaping and leading global commercial, sales and operational strategies, she most recently held a decade-long tenure at Illumina, Inc. where she served as Chief Commercial Officer for three years until joining DELFI in January 2024. Susan spearheaded the engineering and launch of several of Illumina’s most impactful and well-recognized products, and is adept at driving value and commercial success for organizations. Earlier at Illumina, she led the product development organization as Chief Product Officer, and drove the acquisitions of three companies to scale up Illumina’s software solutions. She also brings experience from leadership roles at Eastman Kodak’s Consumer Inkjet Systems as Corporate Vice President and General Manager, Phogenix Imaging LLC and Hewlett-Packard. Susan is a 2022 Forbes ‘50 over 50 Entrepreneurs’ honoree and was named one of the 50 Top Diverse Leaders for 2020 by the California Diversity Council. She is a member of the National Academy of Engineers and the International Women’s Forum, a global organization of preeminent women of significant and diverse achievement. Susan holds an MBA degree from UCLA and an Honors BS in Engineering Science and Mechanics from Pennsylvania State University.

Tom is the Chief Financial Officer (CFO) of DELFI. He has three decades of diverse industry experience, including in finance, operations, and commercialization for public biopharma companies, as well as in the investment community. Prior to DELFI, Tom was CFO of Icosavax, during a pivotal growth period from its initial public offering through its acquisition by AstraZeneca for up to $1.1 billion. At Icosavax and in his prior CFO role at Assembly Bio, he contributed to over $500 million of gross proceeds raised through the capital markets and non-dilutive sources of financing. Previously, Tom held roles across finance and commercial operations at Gilead Sciences, Inc., including serving as Vice President, Head of Commercial Finance. In that role, he supported a $20–30 billion revenue business across North America, Europe, Asia, and emerging markets. Prior to Gilead, Tom was Equity Research Senior Analyst covering biotechnology for Robert W. Baird & Co, where he earned WSJ Best on the Street recognition. Earlier in his career, he held roles of increasing responsibility at Merck & Co. Tom received a BS in biological sciences from the University of Notre Dame and an MBA from the University of Chicago Booth School of Business. He is a CFA charterholder.

Health policy and payment expert, pulmonary physician, and lung cancer epidemiologist, Peter has devoted his career to repairing defects in the healthcare delivery system that impede access to high-quality cancer care and working to ameliorate healthcare’s cost crisis. His work spans seminal studies including that identification of racial gaps in lung cancer care, the development of the first lung cancer risk prediction model (the “Bach model”), lead authorship on multiple lung screening guidelines, and definitional work on pharmaceutical pricing and value. Peter previously served as Senior Adviser at the US Centers for Medicare & Medicaid Services and mentor on many National Institutes of Health K awards. He has been elected to the National Academy of Medicine, American Society for Clinical Investigation, and the Johns Hopkins Society of Scholars.

Amoolya Singh, PhD is Chief Technology Officer at DELFI Diagnostics. Previously, she was Senior Vice President of Research and Chief Scientific Officer at GRAIL, and prior to that, she was Head of Discovery at Calico Life Sciences, where she catalyzed multiple productive collaborations between computational groups and experimental groups. Amoolya earned a PhD in computational biology and a MS in computer science at the University of California at Berkeley. She holds a BS degree in biology and computer science from Carnegie Mellon. Amoolya completed a postdoctoral fellowship at the European Molecular Biology Lab in Heidelberg, Germany in 2008 and a Computational and Life Sciences fellowship at Emory University in 2011 in comparative genomics and metagenomics, population genetics and experimental evolution.

Nidhi Narang is DELFI’s Vice President of Software and Data Engineering. Nidhi brings over 25 years of experience leading software engineering teams in digital health, connected medical devices, and cloud-based platforms in highly regulated healthcare environments. Before joining DELFI, Nidhi spent 14 years at Abbott Laboratories (and St. Jude Medical prior to its acquisition), most recently as Senior Director of R&D where she led the Digital Software & Operations portfolio for Abbott’s Cardiac Rhythm Management division, directing global teams of 200+ professionals developing remote and in-clinic monitoring solutions for patients with implanted cardiac devices. Nidhi has also held leadership roles at Stryker Endoscopy and Siemens Enterprise Networks. She earned her Bachelor of Engineering in Computer Science and Engineering from the National Institute of Technology Allahabad, India, and completed Stanford Biodesign and AI certifications from UC Berkeley. Nidhi serves as an Industry Representative for the FDA Digital Health Advisory Board and is deeply committed to building innovative solutions that improve patient outcomes.

Lee-Ann most recently served as Associate General Counsel at Twist Bioscience, handling intellectual property, commercial, marketing and procurement legal matters. Prior to that, she specialized in patent preparation, prosecution, and strategy in the biotech, biopharma, medical device, computer and chemical fields as a patent attorney at Sheppard, Mullin, Richeter & Hampton LLP and at Zilka-Kotab, PC. She earned her Ph.D. from the University of Southern California and her J.D. from the Santa Clara University School of Law.

Ally is DELFI’s Vice President of People. She joined DELFI in 2021 as Director of Talent Acquisition and in 2022 took on leading the People team and driving the people strategy. Ally has a proven track record of building high-performance, mission-driven cultures that enable everyone to be the best they can be.

Before joining DELFI, Ally led recruiting and managed HR Business Partnering at 23andMe. After kicking off her career in the nonprofit sector as a health educator, Ally moved into the tech and biotech industries at companies like Netflix and Coherus BioSciences.

Ally earned her Bachelor’s of Art in Community Studies from University of California at Santa Cruz.

Victor is internationally known for his discoveries in genomics and cancer research. He and his colleagues performed the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene-expression analyses and coined the word “transcriptome” to describe the patterns that could now be obtained in cancer and other cells. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. These efforts have led to new FDA-approved therapies and diagnostic tests widely used for patients with cancer. More recently, his group has developed noninvasive liquid biopsy approaches for early detection and monitoring of patients with cancer. These discoveries provide new paradigms for our understanding of human cancer that have benefited patients worldwide.

Michaela is the Vice President of Quality, Regulatory, and Laboratory Operations at DELFI. She has been a corporate executive for more than 25 years, and has leveraged her management experience into that of leader, career coach, speaker, and author. Michaela has had a remarkable career in laboratory operations, quality, and regulatory roles at companies in the biotechnology, diagnostic, and pharmaceutical sectors, including Syntex, Veracyte, and Roche. She wrote, “Let Them Lead – how to command less and accomplish more”, a book on servant leadership.

Michaela shares her life with a number of close friends, is immensely proud of her two grown children, Kyle and Nikki, and loves to ride and show her Arabian horses.

Tim brings three decades of genomics research, product development, and diagnostics experience to DELFI Diagnostics. Prior to DELFI, as a senior vice president at TGen, he oversaw Ashion Analytics, a diagnostics laboratory, acquired by Exact Sciences in 2021. Before that he was at Illumina, where he led programs to develop the company’s core next-generation sequencing consumables, launching more than 25 products and helping to grow the company from a startup into the world’s leading genomic sequencing technology provider. A molecular biologist by training, Tim was a Damon Runyon Postdoctoral Fellow at Stanford and earned his PhD from the University of Maryland, Baltimore and BA from UC Santa Barbara.

Dave is DELFI’s Vice President of Clinical Development. He joined DELFI from Roche Diagnostics, where he spent more than a decade in clinical development roles focused on oncology screening and diagnostic products, most recently as Global Head of Clinical Development for Oncology and Genetics. Prior to Roche, Dave led Clinical Affairs at Endocyte, a clinical-stage pharmaceutical company acquired by Novartis in 2018, focusing on both therapeutic and companion diagnostic clinical evidence generation. Before that, he managed multiple clinical studies at Merck. He received a PhD in Microbiology and Immunology from Indiana University.

Sarah Moseley is DELFI’s Vice President of Medical Affairs. Sarah brings over 25 years of experience spanning pharma R&D, molecular diagnostics, Precision Medicine and cancer screening, supporting the launch of over 25 breakthrough products globally. Before joining DELFI, Sarah held a number of roles at GRAIL Inc where she led International Medical Affairs and Implementation; built the US Medical Affairs team introducing a Multi-Cancer Detection test to US healthcare, and led launch strategy and implementation in new markets Internationally. Sarah has also held leadership roles at AstraZeneca and Roche Diagnostics advancing precision medicine and diagnostic innovation. Sarah earned her Ph.D. in Molecular and Cellular Genetics from UC Santa Cruz, completed a postdoctoral fellowship at UCSF, and holds a B.Sc. in Biochemistry from the University of East Anglia UK. Sarah is deeply committed to building strong, collaborative teams and driving innovation at the cutting edge, with a focus on improving outcomes and transforming the patient experience.

Rob Guigley is an experienced executive leader in healthcare technology, digital health, and diagnostics, known for his innovative, strategic and collaborative approach to commercial and operational leadership. With extensive experience in executive-level sales, market access, revenue management, and product development, Rob has successfully grown and transformed organizations to achieve profitable growth. Recently serving as the Chief Commercial Officer at Invitae in San Francisco, Rob orchestrated a major commercial reorganization aimed at transitioning to a sustainable profit model. Prior to Invitae, Rob was the Chief Commercial Officer at Ambry Genetics and served in impactful leadership roles at Omada Health and Counsyl. Rob holds an MBA with honors from Boston University and a Bachelor’s degree in Economics from the University of Pittsburgh. He spends much of his free time supporting his daughter Brynn and son Emerson at their softball, baseball and soccer games.

Cindy brings over 15 years of finance experience. Most recently, Cindy oversaw the finance teams at Zogenix and played a key role in the company’s sale to UCB and post-sale integration efforts. Prior to that she held roles of increasing responsibility over her 8 years at BioMarin Pharmaceuticals with broad experience across pre-clinical, clinical and commercial stage programs. Earlier in her career, Cindy provided assurance and advisory services to private and public companies at PwC. Cindy earned an MS in Accounting from the University of South Florida and is a licensed CPA in California.

Roberto is Vice President of Data Science. He joined the company from LifeMine Therapeutics, where he served as Vice President of Omics & AI, directing the development of novel AI methods to find human and antifungal targets. Prior to LifeMine, Roberto was Vice President of AI Engineering at ConcertAI, where he started the AI engineering team to develop ML-driven approaches for providing insights in Electronic Health Records. Before that, he held several leadership roles at Aitia Bio, culminating as Vice President of Technology, and led the development and release of the company’s Causal AI/ML platform. He received a PhD in Chemical Physics from Harvard University and completed a postdoctoral fellowship at Princeton University.